|Bid||220.07 x 100|
|Ask||233.00 x 200|
|Day's Range||226.62 - 251.99|
|52 Week Range||167.98 - 256.64|
|PE Ratio (TTM)||46.99|
|Earnings Date||Apr 23, 2018 - Apr 27, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||259.31|
LONDON, UK / ACCESSWIRE / April 26, 2018 / Active-Investors.com has just released a free research report on Intec Pharma Ltd (NASDAQ: NTEC). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=NTEC as the Company's latest news hit the wire. On April 24, 2018, the Company, which is a clinical-stage biopharmaceutical organization focused on developing drugs based on its proprietary Accordion Pill platform technology, declared that it presented data from two Phase-1 studies of its proprietary Accordion Pill Carbidopa/Levodopa (AP-CD/LD) for Parkinson's disease at the American Academy of Neurology 2018 Annual Meeting (AAN 2018), in Los Angeles.
Edwards Lifesciences Corp (NYSE:EW) and Illumina, Inc. (NASDAQ:ILMN) reported their quarterly earnings results after hours Tuesday, while Tesla Inc (NASDAQ:TSLA) finds itself in hot waters over a contract dispute. Edward Lifesciences reported its latest quarterly results after hours yesterday. The company announced that the first-quarter global sales of its heart valves, a metric that marks the company’s most important growth driver, increased 2.3% year-over-year to $551.5 million.
The genomic-sequencing pioneer's momentum continues thanks to sustained strong sales for its NovaSeq system launched last year.
On a per-share basis, the San Diego-based company said it had profit of $1.41. Earnings, adjusted for one-time gains and costs, came to $1.45 per share. The results topped Wall Street expectations. The ...
NEW YORK, NY / ACCESSWIRE / April 24, 2018 / Illumina, Inc. (NASDAQ: ILMN ) will be discussing their earnings results in their Q1 Earnings Call to be held on April 24, 2018 at 5:00 PM Eastern Time. To ...
SAN DIEGO, CA / ACCESSWIRE / April 23, 2018 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Illumina, Inc. (ILMN). Investors, who purchased shares of Illumina, Inc. (ILMN) in June 2016 or earlier and continue to hold any of those NASDAQ: ILMN shares, have also certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554. On December 16, 2016, a lawsuit was filed against Illumina, Inc. over alleged securities laws violations.
During the first two quarters of 2016, the Company, which provides genetic sequencing products to customers in the medical, academic, and pharmaceutical industries, repeatedly forecasted to investors an increase in sales of its HiSeq product system for the second half of 2016. On October 10, 2016, the Company disclosed that it had missed its earnings forecast for 2016Q3 by $18 million, driven by lower than expected sales of the HiSeq system. Then, on a November 1, 2016 investor conference call, the Company revealed that an increasing trend of customers preferring its other products over the HiSeq did not immediately show up in 2016Q3 but had been building over time, despite its prior forecasts of increased sales of the product.
Illumina Inc. shares rose in the extended session Friday after the DNA sequencing company and Bristol-Myers Squibb Co. announced they'll use Illumina's next-generation sequencing technology to develop ...
Drug giant Bristol-Myers Squibb is partnering with Illumina, the leading maker of DNA sequencing gear, to develop diagnostic tests that will pair with Bristol's cancer drugs.
Bristol-Myers Squibb Company and Illumina, Inc. today announced a collaboration that will utilize Illumina’s next-generation sequencing technology to develop and globally commercialize in-vitro diagnostic assays in support of Bristol-Myers Squibb’s oncology portfolio.
Illumina's new Lincoln Centre R&D campus in Foster City, developed by BioMed Realty, initially will consolidate 400 employees from four Bay Area locations. Included in the ranks is the company's new CEO.
Drug developer Loxo Oncology said on Tuesday it is partnering with genetic testing company Illumina Inc on a diagnostic tool that will work with Loxo's larotrectinib and another one of its experimental cancer drugs, across tumor types. The companies said the partnership will seek approval for a version of Illumina's test, TruSight Tumor 170, which will allow local laboratories to provide referring physicians with comprehensive genomic information, so that patients can be matched to the most appropriate therapeutic options. Larotrectinib directly targets an acquired rather than inherited genetic defect called TRK fusions.
Loxo Oncology is partnering with genetic testing company Illumina Inc to use Illumina's diagnostic tool alongside larotrectinib, the drug developer's potential blockbuster drug, the companies said on Tuesday. The partnership will seek approval for a version of the Illumina's test, TruSight Tumor 170, as a companion diagnostic for Loxo's larotrectinib and another one of Loxo's experimental cancer drugs, across tumor types.
-Expands Illumina’ s Oncology Offerings for NextSeq™ 550 Dx with a Companion Diagnostic Version of TruSight™ Tumor 170 for Solid Tumors-. -Loxo Oncology to Utilize a Companion Diagnostic Version of TruSight ...
Illumina, Inc. and Loxo Oncology today announced a global strategic partnership to develop and commercialize a multi-gene panel for broad tumor profiling, resulting in a distributable, next-generation sequencing based companion diagnostic with a pan-cancer indication.
Illumina, Inc. today announced that it will issue results for first quarter 2018 following the close of market on Tuesday, April 24, 2018.